Free Trial

Anika Therapeutics Q2 2023 Earnings Report

Anika Therapeutics logo
$16.62 -0.32 (-1.89%)
(As of 12/17/2024 ET)

Anika Therapeutics EPS Results

Actual EPS
-$0.06
Consensus EPS
-$0.27
Beat/Miss
Beat by +$0.21
One Year Ago EPS
N/A

Anika Therapeutics Revenue Results

Actual Revenue
$44.30 million
Expected Revenue
$40.61 million
Beat/Miss
Beat by +$3.69 million
YoY Revenue Growth
N/A

Anika Therapeutics Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Slide Deck

Musk threatens Liberal’s fake “energy crisis” (Ad)

Elon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.

To get the full details on the fake “energy crisis” of America, watch this now

Anika Therapeutics Earnings Headlines

Anika To Participate in December 2024 Investor Conferences
Anika Therapeutics Navigates Geopolitical Risks Amid Global Conflicts
Do this Before Elon’s Reveal on January 22nd
Elon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but designed to power a $9 trillion AI revolution. And I’ve identified a little-known supplier Elon is depending on to make it all happen.
Anika Therapeutics price target lowered to $25 from $37 at Barrington
Anika (ANIK) Earnings Dates & Reports
See More Anika Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Anika Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Anika Therapeutics and other key companies, straight to your email.

About Anika Therapeutics

Anika Therapeutics (NASDAQ:ANIK), a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, sports medicine, and arthrosurface joint solutions in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management products includes Monovisc and Orthovisc, an injectable HA-based viscosupplement for the pain relief from osteoarthritis conditions; and Cingal, a single-injection OA pain management product to provide both short- and long-term pain relief. The company's joint preservation and restoration product family comprises and orthopedic regenerative solutions, including Hyalofast and Tactoset; sports medicine solutions used to repair and reconstruct damaged ligaments and tendons; and preserving joint solutions, including partial joint replacement, joint resurfacing, and invasive and bone sparing implants, which are designed to treat upper and lower extremity orthopedic conditions. In addition, it offers non-orthopedic products comprising HA-based products for non-orthopedic applications including Hyvisc, a molecular weight injectable HA veterinary product; Hyalobarrier, an anti-adhesion barrier indicated for use after abdominal-pelvic surgeries; and Hyalomatrix used for the treatment of burns and ulcers, as well as products used for the treatment of ears, nose and throat disorders, and ophthalmic products. The company was founded in 1983 and is headquartered in Bedford, Massachusetts.

View Anika Therapeutics Profile

More Earnings Resources from MarketBeat

Upcoming Earnings